Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 4 2Phase 1 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 67Breast Neoplasms, Male 4Neoplasm Metastasis 3Neoplasms 2Advanced Breast Cancer 2Unilateral Breast Neoplasms 1Sleep Wake Disorders 1Recurrence 1Ovarian Neoplasms 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1First Line Metastatic Breast Cancer 1Fatigue 1Carcinoma, Intraductal, Noninfiltrating 1Bulbo-Spinal Atrophy, X-Linked 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Breast Cancer Female 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Leucovorin 22Fluorouracil 22Paclitaxel 21Gemcitabine 21Docetaxel 21Capecitabine 21Irinotecan 16Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × exemestane × Clear all
NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Eli Lilly and Company

Phase 3 Recruiting
920 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02404051 2016-06-15

FEVEX

Consorzio Oncotech

Phase 3 Unknown
745 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡